GE
65
4
AIV
54
3
NVDA
57
2
OMC
64
2
CTSH
63
6
THC
64
-3
LMT
34
5
AFL
44
3
LUV
43
3
AME
69
7
MUR
50
6
AES
38
-6
AMP
78
12
SLG
69
3
MS
80
11
PX
69
3
FITB
65
13
CTAS
59
6
F
59
17
FLS
76
7
GE
65
4
AIV
54
3
NVDA
57
2
OMC
64
2
CTSH
63
6
THC
64
-3
LMT
34
5
AFL
44
3
LUV
43
3
AME
69
7
MUR
50
6
AES
38
-6
AMP
78
12
SLG
69
3
MS
80
11
PX
69
3
FITB
65
13
CTAS
59
6
F
59
17
FLS
76
7
Financhill
Back

Arcturus Therapeutics Holdings 10K Form

Sell
38

ARCT
Arcturus Therapeutics Holdings

Last Price:
18.25
Seasonality Move:
9.45%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2020-08-10 10Q ARCT/Arcturus Therapeutics Holdings Quarterly
2020-05-08 10Q ARCT/Arcturus Therapeutics Holdings Quarterly
2020-03-16 10K ARCT/Arcturus Therapeutics Holdings Annual
2019-11-08 10Q ARCT/Arcturus Therapeutics Holdings Quarterly
2019-08-14 10Q ARCT/Arcturus Therapeutics Holdings Quarterly

Receive ARCT News And Ratings

See the #1 stock for the next 7 days that we like better than ARCT

ARCT Financial Statistics

Sales & Book Value

Annual Sales: $157.75M
Cash Flow: $-30.47M
Price / Cash Flow: 0
Annual Sales: $9.56
Price / Book: 1.92

Profitability

EPS (TTM): -2.57000
Net Income (TTM): $-71.96M
Gross Margin: $0
Return on Equity: -26.34%
Return on Assets: -16.93%

Arcturus Therapeutics Holdings Earnings Forecast

Key Arcturus Therapeutics Holdings Financial Ratios

  • The Selling, General & Administrative Expenses for ARCT have been equal to 33.52% of Gross Profit Margin.
  • The Research & Development expenses have been 121.80% of Revenue.
  • The Interest Expense is -2.58% of Operating Income.
  • The Net Earning history of ARCT is -18.84% of Total Revenues.
  • Per Share Earnings over the last 13 years have been positive in 6 years.

Arcturus Therapeutics Holdings Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ARCT
CUSIP: M1492T
Website: arcturusrx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 3.78
Quick Ratio: 3.1

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ARCT Technical Analysis vs Fundamental Analysis

Sell
38
Arcturus Therapeutics Holdings (ARCT) is a Sell

Is Arcturus Therapeutics Holdings a Buy or a Sell?